The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy-Reference-Cited by-同舟云学术

The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

Published:2015-07 Issue:1 Volume:86 Page:92-98
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Soave Armin,John Lisa-Marie,Dahlem Roland,Minner Sarah,Engel Oliver,Schmidt Selina,Kluth Luis A.,Fisch Margit,Rink Michael

Publisher

Elsevier BV

Subject

Urology

Reference25 articles.

1. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2013 guidelines;Witjes;Eur Urol,2014

2. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy;Rink;BJU Int,2013

3. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer;J Clin Oncol,2006

4. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder;Nuhn;Eur Urol,2012

5. Can we apply nomograms derived in the United States to European patients? Yes, we can!;Rink;Eur Urol,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor necrosis in magnetic resonance imaging predicts urothelial carcinoma with squamous differentiation in muscle-invasive bladder carcinoma;Abdominal Radiology;2024-08-02

2. Determining the clinicopathological significance of the VI-RADS ≧4 group: a retrospective study;BMC Urology;2024-03-20

3. Macroscopy of specimens from the genitourinary system;Journal of Clinical Pathology;2024-02-19

4. Determining the clinicopathological significance of the VI-RADS true-positive group: A retrospective study;2023-04-13

5. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial;Cancers;2023-03-13